Participant timeline {13}
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, ADVERSE EVENTS
Patients will be followed till 90 days after the last cycle of paclitaxel or 90 days after the development of grade 2 or higher chemotherapy-induced peripheral neuropathy, whichever occurs earlier. Data collected for the study comprises clinical characteristics (obtained prospectively during the study and routine laboratory investigations), including but not limited to baseline demographics, outcome measures, treatment details, and adverse events at each 3 weekly visit (Fig. SPIRIT figure